We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-18.32%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$875M
AUM Growth
-$123M
Cap. Flow
+$83.4M
Cap. Flow %
9.54%
Top 10 Hldgs %
28.77%
Holding
95
New
7
Increased
32
Reduced
30
Closed
6

Top Buys

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$14M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$11.4M
3
CNC icon
Centene
CNC
+$10.7M
4
BIIB icon
Biogen
BIIB
+$9.57M
5
UNH icon
UnitedHealth
UNH
+$9.35M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$10.1M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.4M
3
INCY icon
Incyte
INCY
+$7.17M
4
LOXO
Loxo Oncology, Inc
LOXO
+$6.07M
5
EXEL icon
Exelixis
EXEL
+$5.39M

Sector Composition

Rank Sector Weight
1 Healthcare 93.94%
2 Energy 0.12%
3 Technology 0.11%
4 Financials 0.09%
5 Communication Services 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMO icon
51
Thermo Fisher Scientific
TMO
$220B
$6.71M 0.77%
+30,000
New +$7.04M
REGN icon
52
Regeneron Pharmaceuticals
REGN
$80.8B
$6.35M 0.73%
17,000
– –
OMCL icon
53
Omnicell
OMCL
$1.68B
$6.15M 0.7%
100,375
– –
AGIO icon
54
Agios Pharmaceuticals
AGIO
$1.93B
$5.86M 0.67%
127,012
-18,416
-13% -$1.14M
FLXN
55
DELISTED
Flexion Therapeutics, Inc.
FLXN
$5.74M 0.66%
506,965
-25,847
-5% -$405K
RIGL icon
56
Rigel Pharmaceuticals
RIGL
$750M
$5.21M 0.6%
226,494
+15,095
+7% +$426K
ALKS icon
57
Alkermes
ALKS
$8.25B
$5.15M 0.59%
174,399
-127,211
-42% -$4.69M
PTLA
58
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$4.72M 0.54%
241,964
-338
-0.1% -$6.95K
ABEO icon
59
Abeona Therapeutics
ABEO
$413M
$4.63M 0.53%
+25,965
New +$5.66M
MD icon
60
Pediatrix Medical
MD
$2.2B
$4.11M 0.47%
124,674
– –
VRAY
61
DELISTED
ViewRay, Inc.
VRAY
$4.03M 0.46%
664,023
+147,400
+29% +$1.1M
RVNC
62
DELISTED
Revance Therapeutics, Inc.
RVNC
$3.89M 0.44%
193,181
-10,000
-5% -$220K
MRTX
63
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.61M 0.41%
+85,000
New +$3.39M
ONCE
64
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$3.46M 0.4%
88,302
-49,389
-36% -$2.14M
GTHX
65
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$3.31M 0.38%
+172,820
New +$6.47M
CHRS icon
66
Coherus Oncology
CHRS
$196M
$2.91M 0.33%
321,131
-10,000
-3% -$116K
MDCO
67
DELISTED
Medicines Co
MDCO
$2.58M 0.3%
135,000
– –
LOXO
68
DELISTED
Loxo Oncology, Inc
LOXO
$1.4M 0.16%
10,000
-40,000
-80% -$6.07M
LH icon
69
Labcorp
LH
$25.9B
$1.39M 0.16%
+12,804
New +$1.72M
ADMS
70
DELISTED
Adamas Pharmaceuticals
ADMS
$1.37M 0.16%
159,924
-113,669
-42% -$1.48M
AMRN
71
Amarin Corp
AMRN
$303M
$1.36M 0.16%
+5,000
New +$1.82M
PVLA
72
Palvella Therapeutics
PVLA
$2.27B
$798K 0.09%
3,750
– –
ACHN
73
DELISTED
Achillion Pharmaceuticals
ACHN
$640K 0.07%
402,800
-215,000
-35% -$608K
CMRX
74
DELISTED
Chimerix, Inc.
CMRX
$581K 0.07%
226,080
-115,220
-34% -$386K
XOM icon
75
ExxonMobil
XOM
$634B
$417K 0.05%
6,111
– –
1 2
3
4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2018 Portfolio in Review

As of Q4 2018, Rhenman & Partners Asset Management held 95 positions worth $875M, down 12% from $998M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $83.4M of net new capital in Q4 2018, opening 7 new positions and adding to 32 existing holdings. Its largest new stake was bluebird bio: 9,098 shares worth $11.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 91% a quarter earlier, followed by Energy and Technology.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $8.4M trimmed.

  • Rhenman & Partners Asset Management's largest Q4 2018 buy was bluebird bio: 9,098 shares worth $11.7M.
  • Rhenman & Partners Asset Management added most to Neurocrine Biosciences in Q4 2018, an estimated $11.4M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2018 reduction was BioMarin Pharmaceuticals, cutting an estimated $8.4M.
  • Rhenman & Partners Asset Management fully exited Aetna Inc in Q4 2018, selling an estimated $10.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $875M portfolio in Q4 2018.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 6 in Q4 2018.
  • Rhenman & Partners Asset Management's portfolio value fell 12% quarter-over-quarter to $875M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2018, filed 5 Feb 2019.